ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer

Terrence O. Moore Retires as Chief Commercial Officer

SAN DIEGO—(BUSINESS WIRE)—Mar. 30, 2017—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced Michael J. Yang has joined ACADIA asExecutive Vice President and Chief Commercial Officer. Mr. Yang succeedsTerrence O. Moore, who has served as ACADIA’s Chief Commercial Officersince 2013, and is now retiring.

This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20170330005419/en/

Michael J. Yang, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)

“I am delighted to welcome Michael to our team,” said Steve Davis,ACADIA’s President and Chief Executive Officer. “Michael is a seasonedexecutive with extensive expertise in successfully launching and growingmajor pharmaceutical products across a number of therapeutic areas,including CNS. His patient-centric approach, proven leadership skills,and focus on innovation will be of great value to the ongoingcommercialization of NUPLAZID in Parkinson’s disease psychosis and itspotential expansion into other areas of large unmet need.”

“Central nervous system disorders are one of the biggest challenges toour healthcare system and severely impact the lives of both patients andtheir families,” said Michael Yang. “As an innovative, first-in-classproduct, NUPLAZID is transforming the treatment of patients sufferingfrom Parkinson’s disease psychosis. I look forward to building on thesuccess of NUPLAZID.”

“We thank Terry Moore for his significant contributions to ACADIA overthe past four years,” added Mr. Davis. “Under his leadership, we havelaid a strong foundation for the continued growth of NUPLAZID. We wishhim well in his retirement as he plans to move back to the East Coastand spend more time with his family.”

Mr. Moore commented, “I am proud of what we have been able to achieve –building the commercial foundation, launching NUPLAZID, and bringingthis novel drug to patients in need. After more than 30 years in thelife sciences industry, I’m pleased to hand the reins over to Michael tolead the next phase of growth for ACADIA, and I look forward to watchingthe company reach new levels of success.”

Mr. Yang joins ACADIA from Janssen Pharmaceutical Companies of Johnson &Johnson, where he served as President of Janssen Biotech Inc. and wasresponsible for building Janssen's U.S. Immunology business, generatingmore than $8 billion in annual revenues. Mr. Yang began his career atJohnson & Johnson in 1997 and held numerous senior commercial positionssuch as President, CNS where he was responsible for growing theanti-psychotic long-acting therapy portfolio. His broad background ofcommercialization and general management experience also includes rolesas the Worldwide General Manager of the Medical Device companies ofTherakos, Inc and Veridex, LLC, where he launched new platforms,expanded global revenues and diversified the product lines. Prior tothat, Mr. Yang was Vice President of Sales and Marketing, Oncology atOrtho Biotech Inc.

Mr. Yang earned his Bachelor of Science degree in BusinessAdministration, Marketing from San Diego State University. Mr. Yang willserve as a member of ACADIA’s executive team and report to Mr. Davis,effective today.

About NUPLAZID^® (pimavanserin)

NUPLAZID is the first and only FDA-approved treatment for hallucinationsand delusions associated with Parkinson’s disease (PD) psychosis.NUPLAZID is a non-dopaminergic, selective serotonin inverse agonistpreferentially targeting 5-HT_2A receptors that are thought toplay an important role in PD Psychosis. NUPLAZID is an oral medicinetaken once a day with a recommended dose of 34 mg (two 17-mg tablets).ACADIA discovered this new chemical entity and holds worldwide rights todevelop and commercialize NUPLAZID.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the benefits to be derived fromNUPLAZID (pimavanserin); the utility or expansion of pimavanserin inindications other than hallucinations and delusions associated with PDPsychosis; and any future growth or success of NUPLAZID or ACADIA. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development, andcommercialization, and the fact that past results of clinical trials maynot be indicative of future trial results. For a discussion of these andother factors, please refer to ACADIA’s annual report on Form 10-K forthe year ended December 31, 2016 as well as ACADIA’s subsequent filingswith the Securities and Exchange Commission. You are cautioned not toplace undue reliance on these forward-looking statements, which speakonly as of the date hereof. This caution is made under the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.

Important Safety Information and Indication forNUPLAZID (pimavanserin) tablets

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITHDEMENTIA-RELATED PSYCHOSIS
Elderly patients withdementia-related psychosis treated with antipsychotic drugs are at anincreased risk of death. NUPLAZID is not approved for the treatment ofpatients with dementia-related psychosis unrelated to the hallucinationsand delusions associated with Parkinson’s disease psychosis.

NUPLAZID is an atypical antipsychotic indicated for the treatment ofhallucinations and delusions associated with Parkinson’s diseasepsychosis.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use ofNUPLAZID should be avoided in patients with known QT prolongation or incombination with other drugs known to prolong QT interval includingClass 1A antiarrhythmics or Class 3 antiarrhythmics, certainantipsychotic medications, and certain antibiotics. NUPLAZID should alsobe avoided in patients with a history of cardiac arrhythmias, as well asother circumstances that may increase the risk of the occurrence oftorsade de pointes and/or sudden death, including symptomaticbradycardia, hypokalemia or hypomagnesemia, and presence of congenitalprolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2%for NUPLAZID and greater than placebo) were peripheral edema (7%vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination(5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole)increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half.Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reducedefficacy. Increase in NUPLAZID dosage may be needed.

Renal Impairment: No dosage adjustment for NUPLAZID is needed inpatients with mild to moderate renal impairment. Use of NUPLAZID is notrecommended in patients with severe renal impairment.

Hepatic Impairment: Use of NUPLAZID is not recommended in patients withhepatic impairment. NUPLAZID has not been evaluated in this patientpopulation.

Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated andshould therefore be used in pregnancy only if the potential benefitjustifies the potential risk to the mother and fetus.

Pediatric Use: Safety and efficacy have not been established inpediatric patients.

Dosage and Administration: Recommended dose: 34 mg per day, taken orallyas two 17-mg tablets once daily, without titration.

For additional Important Safety Information, including boxed warning,please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:
ACADIA Pharmaceuticals Inc.
LisaBarthelemy
(858) 558-2871
ir@acadia-pharm.com
or
MediaContact:
Taft Communications
Bob Laverty
(609)558-5570
bob@taftcommunications.com